Please ensure Javascript is enabled for purposes of website accessibility

Why Cronos Group Shares Soared Today

By Keith Speights – Updated Apr 23, 2019 at 9:23PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Possible good news for the U.S. cannabis industry appeared to provide a boost to this top Canadian marijuana stock.

What happened

Shares of Cronos Group (CRON -3.83%) soared 14.1% as of 3:16 p.m. EST on Monday. The marijuana stock appeared to receive a boost from U.S. attorney general nominee William Barr's written response to questions from the Senate Judiciary Committee. In this response, Barr confirmed his previous testimony before the committee that he would not target cannabis businesses that comply with individual states' marijuana laws.

So what

Cronos wasn't the only Canadian marijuana stock to jump after Barr's written pledge made news. Several of the company's peers also enjoyed nice gains on Monday, including Aurora Cannabis, Canopy Growth, and Tilray

Hands holding $100 bills and a marijuana leaf

Image source: Getty Images.

But none of the other top marijuana stocks moved as much as Cronos did. That's possibly because Cronos claims a lower market cap than others and could be perceived as a more attractive bargain by investors.

There's also the fact that -- other than Canopy Growth, which claims a market cap more than five times greater than Cronos -- only Cronos Group has landed a big investment from a major partner outside the cannabis industry. In December, tobacco giant Altria bought a 38% stake in Cronos for $1.8 billion.

Did the written statement from Barr justify such a major rise for Cronos? Not really. As of now, Cronos and the other major Canadian marijuana growers can't establish operations in the U.S. marijuana market and retain their listings on U.S. stock exchanges or the Toronto Stock Exchange.

However, Barr's written response indicates that the Trump administration won't be hostile toward the cannabis industry. That's potentially good news for Canadian companies that plan to enter the U.S. hemp market following the recent legalization of hemp in the U.S. It also reinforces optimism that the administration might support congressional efforts to revise federal laws in a way that would allow Canadian companies to legally operate in the U.S. marijuana market.

Now what

Investors will certainly want to watch if Cronos Group makes any moves to enter the U.S. hemp market. Such an expansion would likely be made in lockstep with Altria.

In the meantime, the most important thing for Cronos is executing on its strategy in the Canadian recreational marijuana market. The company posted huge revenue growth in Q3, but its numbers didn't include any sales from recreational marijuana products. When Cronos reports its next quarterly results, investors should have a lot more to cheer about.   

Check out the latest Cronos Group earnings call transcript.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cronos Group Inc. Stock Quote
Cronos Group Inc.
CRON
$3.01 (-3.83%) $0.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
351%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.